





1


Lifecourse Approaches to Atrial Fibrillation: Focus on Prevention & Social Drivers

Emelia J. Benjamin, MD, ScM, DrHC
Ad Interim Dean for Faculty Development, Boston University (BU) CAMEd
Coffman Professor of Vascular Medicine,
BU Chobanian & Avedisian School of Medicine
Professor Epidemiology, BU School of Public Health
Honorary Doctorate Medical Science, Aalborg University, Denmark
NHLBI & Boston University’s Framingham Heart Study





GRAND
ROUNDS



























2

Disclosures

- **AF** R01HL092577
- **Pain** R01AG066010; 1R01AG066914; 1R01NS121419
- **NHLBI** **Co-Chair, AF Research Working Group**
 - Screening. *Circulation*. 2021;143:372
 - 2° Prevention. *JAHA*. 2021;10:e021566
 - AF Social Determinants. *JAMA Cardiol*. 2023;8:182

3

 Framingham Study Martin G. Larson ★ Kathryn L. Lunetta Honghuang Lin Betty Liu Karen Mutalik Jelena Kornej Lisa M. Sullivan Jared W. Magnani Dan Levy Thomas J. Wang ★ Ludovic Trinquart Darae Ko Sarah Preis O Benjamin Eromosele	 German AF Network Moritz F. Sinner Stefan Kääb AGES Albert Smith Vilmundur Gudnason ARIC ★ Alvaro Alonso Dan Arking Duke ★ Lesley H. Curtis	 MGH/BWH ★ Steven A. Lubitz ★★ Patrick T. Ellinor Cardiovascular Health Study ★ Susan R. Heckbert BU CAMEd/BMC Robert R Helm Ayelet Shapira-Daniels Cleveland Clinic Mina K. Chung John Barnard David R. van Wagener U. Mass David McManus U. Groningen Michiel Rienstra	 UCLA Utibe Essien
 Hamburg Health Study Renate B. Schnabel	 Danish Study Lars Frost Nicklas Vinter Tanja C. Frederiksen ★ 1R01HL092577 & 1R01HL128914 ★ 1RC1 HL101056 ★ 1R01 HL102214 ★ AHA 18SFRN34110082	        	        

4

Learning Objectives


- Practice primary & secondary prevention of AF
- Understand data linking SDOH to AF
- Identify critical research priorities to improve health outcomes in AF

5

Background – Atrial Fibrillation

Prevalence
Incidence
Outcomes

6



7


Five Year Risk of AF – CHARGE-AF Model

5 Year AF Risk Predictione	↓	Enter Values Here
Risk Factor	Units	
Age	years	68
Race (White)	yes or no	Yes
Height	inches	72.0
Weight	pounds	220.0
Smoking	yes or no	no
Systolic Blood Pressure	mm Hg	145
Diastolic Blood Pressure	mm Hg	75
Hypertension Treatment	yes or no	yes
Diabetes	yes or no	no
History of Heart Failure	yes or no	Yes
History of Myocardial Infarction	yes or no	no
YOUR RISK (Simple Model)	>26%	←
NORMAL	7.6%	←
OPTIMAL	6.8%	


Background

•Alonso *J Am Heart Assoc*. 2013;2:e000102


8



9




10



11

AF & HF: Disease Progression & Treatment



2° Prevention: AF

• Zeitler JACC Heart Fail 2024;12:1528


12




13




14




15




16



17



18




19

CLINICAL PRACTICE GUIDELINES		
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines		
Recommendation for Primary Prevention		
COR	LOE	Recommendation
1	B-NR	1. Patients at increased risk of AF should receive comprehensive guideline-directed LRFM for AF, targeting obesity, physical inactivity, unhealthy alcohol consumption, smoking, diabetes, & hypertension.


1° Prevention

• Joglar et al. *Circulation*. 2024;149:e1

20



21



22

CLINICAL PRACTICE GUIDELINES

2023 ACC/AHA/ACCP/HRS Guideline for the
Diagnosis and Management of Atrial Fibrillation:
A Report of the American College of Cardiology/
American Heart Association Joint Committee on
Clinical Practice Guidelines

Recommendation for Weight Loss in Individuals Who Are Overweight or Obese		
COR	LOE	Recommendation
1	B-R	1. In patients with AF who are overweight or obese (BMI>27 kg/m ²), weight loss is recommended, with an ideal target of at least 10% weight loss to reduce AF symptoms, burden, recurrence, & progression to persistent AF.


2° Prevention:
AF

•Joglar et al. *Circulation*. 2024;149:e1

23

ACTIVE-AF Study RCT Exercise vs. Control

Exercise led to ↓ Recurrent AF & Improved Symptom Burden
AF Free @12 months HR, 0.50; 95% CI 0.22-0.78



2° Prevention:
AF

• Elliot *J Am Coll Cardiol EP*. 2023;9:455

24

CLINICAL PRACTICE GUIDELINES

2023 ACC/AHA/ACCP/HRS Guideline for the
Diagnosis and Management of Atrial Fibrillation:
A Report of the American College of Cardiology/
American Heart Association Joint Committee on
Clinical Practice Guidelines

Recommendation for Physical Fitness		
COR	LOE	Recommendation
1	B-R	1. In individuals with AF,* moderate to vigorous exercise training to a target of 210 minutes per week is recommended to reduce AF symptoms and burden, increase maintenance of sinus rhythm, increase functional capacity, and improve QOL.


*Without AF related to excessive exercise training

2° Prevention:
AF

•Joglar et al. *Circulation*. 2024;149:e1

25

Quitting Smoking after AF Dx
Associated Significant ↓ in Dementia
Observational Korean National Health Insurance Data



2° Prevention:
Other Outcomes

• Choi *JAMA Netw Open*. 2022; 5:e2217132

26

CLINICAL PRACTICE GUIDELINES

2023 ACC/AHA/ACCP/HRS Guideline for the
Diagnosis and Management of Atrial Fibrillation:
A Report of the American College of Cardiology/
American Heart Association Joint Committee on
Clinical Practice Guidelines


Recommendation for Smoking Cessation		
COR	LOE	Recommendation
1	B-NR	1. Patients with a history of AF who smoke cigarettes should be strongly advised to quit smoking and should receive GDMT for tobacco cessation to mitigate increased risks of AF-related cardiovascular complications and other adverse outcomes.

2° Prevention:
AF

• Joglar et al. *Circulation*. 2024;149:e1

27

Alcohol Abstinence Improved Time to Recurrence AF
RCT Multi-center, open-labelled



2° Prevention:
AF

HR, 0.55; 95% CI, 0.36-0.84; p=0.005

• Voskoboinik *NEJM*. 2020;382:20

28

CLINICAL PRACTICE GUIDELINES


2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Recommendation for Alcohol Consumption		
COR	LOE	Recommendation
1	B-R	1. Patients with AF seeking a rhythm-control strategy should minimize or eliminate alcohol consumption to reduce AF recurrence and burden.

2° Prevention:
AF

Joglar et al. *Circulation*. 2024;149:e1

29



CLINICAL PRACTICE GUIDELINES

2023 ACC/AHA/ACCP/HRS Guideline for the
Diagnosis and Management of Atrial Fibrillation:
A Report of the American College of Cardiology/
American Heart Association Joint Committee on
Clinical Practice Guidelines


Recommendation for the Treatment of Hypertension		
COR	LOE	Recommendation
1	B-NR	1. For patients with AF and hypertension, optimal BP control is recommended to reduce AF recurrence and AF-related cardiovascular events.

2° Prevention:
AF

•Joglar et al. *Circulation*. 2024;149:e1

31

Use of Evidence-Based Cardiac Prevention Therapies in AF
ORBIT-AF, US national registry AF patients



• 93.5% eligible ≥1 evidence-based therapy

Among eligible, 46.6% received all indicated Rx

2° Prevention:
Other Outcomes

• Hess *Am J Med*. 2013; 126:625

32

CLINICAL PRACTICE GUIDELINES

2023 ACC/AHA/ACCP/HRS Guideline for the
Diagnosis and Management of Atrial Fibrillation:
A Report of the American College of Cardiology/
American Heart Association Joint Committee on
Clinical Practice Guidelines

Recommendations for Comprehensive Care		
COR	LOE	Recommendation
1	A	1. Patients with AF should receive comprehensive care addressing guideline-directed LRFM, AF symptoms, risk of stroke, & other associated medical conditions to reduce AF burden, progression, or consequences.
2a	B-R	2. In patients with AF, use of clinical care pathways, such as nurse-led AF clinics, is reasonable to promote comprehensive, team-based care and to enhance adherence to evidence-based therapies for AF and associated conditions.

2° Prevention:
AF


•Joglar et al. *Circulation*. 2024;149:e1

33


Social Determinants of Health

Systemic Barriers:
Education & Socioeconomic Status
Geography and Rurality
Race and Ethnicity


34




35




36




37




38




39




40




41




42




43




44




45



46




47




48



49



50



51

CLINICAL PRACTICE GUIDELINES

2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines

Recommendations to Address Health Inequities & Barriers to AF Management		
COR	LOE	Recommendation
1	B-NR	1. Patients with AF, regardless of sex and gender diversity, race and ethnicity, or adverse social determinants of health (SDOH), should be equitably offered guideline-directed stroke risk reduction therapies as well as rate or rhythm control strategies and LRFM as indicated to improve quality of life (QOL) and prevent adverse outcomes.

Barriers: Systemic & Socioeconomic • Joglar et al. *Circulation*. 2024;149:e1

52

What can we do as Clinicians?




- Diversify our training programs, practices, & research teams
- Utilize multidisciplinary teams & community health workers
- Advocate for policy changes
- Support research to establish evidence-based implementation


https://aida.org.au/app/uploads/2022/03/AIDA-Growing-medical-specialists-report-2021_v2.pdf
Burgess *Intern Med J* 2020;50:412

53

Are You Practicing ?

COMPREHENSIVE RISK FACTOR MANAGEMENT





Benjamin *J Am Heart Assoc.* 2021;10:e021566
<https://tobiasglaser.ch/2018/02/23/the-confidence-meter/>

54

CMS Inpatient Prospective Payment System

3 equity-measures Hospital Inpatient Quality Program

	Voluntary	Mandatory	Payment Determination
Hospital Commitment to Health Equity			2025
Screening for Social Drivers of Health	2023	2024	2026
Screen Positive Rates Social Drivers of Health	2023	2024	2026

FY 2026 Hospital Inpatient Prospective Payment System Proposed Rule — CMS-1833-P Fact Sheet 4/11/2025

CMS is proposing to remove measures:

Remove Hospital Commitment to Health Equity, beginning CY 2024 reporting period/FY 2026 program year

Remove Screening for Social Drivers of Health & Screen Positive Rate for Social Drivers of Health measures, beginning with CY 2024 reporting period/FY 2026 payment determination.

Slide courtesy of Jennifer Mieres, MD Northwell Health;

<https://www.cms.gov/newsroom/fact-sheets/fy-2026-hospital-inpatient-prospective-payment-system-ipp-and-long-term-care-hospital-prospective>

55

The Joint Commission: Reducing Disparities in Quality & Safety

1.Designate Equity Champion

2.Assess social needs & SDoH

3.Stratify key quality & safety data

4.Develop written action plan

5.Monitor effectiveness

6.Annual report

Slide courtesy of Jennifer Mieres, MD Center for Equity of Care & Office of Strategic Planning Northwell Health


https://www.jointcommission.org/-/media/tjc/documents/standards/r3-reports/r3_disparities_july2022-6-20-2022.pdf

R3 Report Issue 36: New Requirements to Reduce Health Care Disparities

56




57



58

NHLBI Workshop AF SDOH Cross-Cutting Research Opportunities




Marked inequities amplified by SDOH across the lifecycle of AF

Summary

Benjamin *JAMA Cardiol.* 2023;8:182

59

Social Drivers of AF



Research
Priorities

• Essien *Nat Rev Cardiol.* 2021;18:763.



60







61

Primary & Secondary Prevention → Equitable Care

- **Primary Prevention, patients @ ↑ risk AF :**
 - Class 1, LOE B-NR should receive Lifestyle & RF management
- **Secondary prevention**
 - Class 1, LOE B-R, obesity, exercise, alcohol limitations or abstinence
 - Class 1, LOE B-NR, smoking cessation, hypertension treatment
 - Class 1, LOE A, comprehensive care for lifestyle & RF management

Summary



62



31 of 32

Social Determinants of AF

AF Guidelines & JAHCO all focus on health equity

Future Research Priorities

- **↑ Diversity**
 - Recruitment & retention diverse patients in observational & pragmatic studies by gender, race/ethnicity, income, education
 - Settings, including communities & rural
- Develop innovative methods to analyze multiple intersectional identities & cumulative disadvantage across the life course
- Pragmatic studies to test multilevel strategies mitigate SDOH in AF diagnosis, management, & outcomes



Summary

Benjamin *JAMA Cardiol.* 2023;8:182